Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London

Nuvation Bio (NUVB) will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 17, 2026.

Rhea-AI Summary

Nuvation Bio (NUVB) will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 17, 2026. Founder, President and CEO David Hung and CFO Philippe Sauvage will speak at 2:30 p.m. GMT. A live webcast will be available through the company's Investor Relations website, with an archived recording available for 90 days following the event.

Key Terms

ros1 inhibitor, idh1 inhibitor

2 terms

ros1 inhibitor medical

"a next-generation ROS1 inhibitor"

A ROS1 inhibitor is a targeted small-molecule drug that blocks the activity of the ROS1 receptor tyrosine kinase, an enzyme that can drive cancer cell growth when the ROS1 gene is abnormally fused or rearranged. By binding to the kinase’s active site, these inhibitors prevent the signaling that promotes tumor cell proliferation and survival; their clinical effect is generally limited to cancers that carry ROS1 rearrangements, and tumor resistance can emerge through secondary mutations or alternative signaling pathways.

idh1 inhibitor medical

"a brain-penetrant IDH1 inhibitor"

A small-molecule drug that binds to and blocks the activity of the isocitrate dehydrogenase 1 (IDH1) enzyme, usually targeting the cancer-associated mutant form of IDH1. Mutant IDH1 produces an abnormal metabolite (2‑hydroxyglutarate) that disrupts cell differentiation; an IDH1 inhibitor reduces that oncometabolite and can restore more normal cellular behavior. Effectiveness depends on the presence of an IDH1 mutation in the tumor—these drugs generally do not work against cancers with only the normal (wild‑type) IDH1 enzyme.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 2:30 p.m. GMT.

A live webcast of the fireside chat will be available on the Investor Relations section of the Nuvation Bio website. An archived recording will be available for 90 days following each event.

About Nuvation Bio 

Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI ^®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program. 

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc). 

Media and Investor Contacts

Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com

Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-to-present-at-the-jefferies-global-healthcare-conference-in-london-302935052.html

SOURCE Nuvation Bio, Inc.